来那度胺相关B细胞急性淋巴细胞白血病:临床与病理相关性及对停用来那度胺的敏感性
双中心回顾性研究分析32例来那度胺维持治疗后发生的ALL(均为B系,31/32 BCR::ABL阴性),中位暴露后54个月诊断,TP53突变9/19可评估病例、低亚二倍体8/26;治疗患者CR/CRi高(25/28),5例停用来那度胺后B-ALL或未成熟B细胞群消退,提示停药可能为选定患者的一线干预。
要点
- 来那度胺相关B-ALL中位诊断时间为首次暴露后54个月,中位累积暴露42个月。
- 可评估病例中TP53突变9/19,低亚二倍体8/26。
- 接受治疗患者CR/CRi达25/28,异基因HCT后中位EFS未达到。
核心结论
- 来那度胺相关B-ALL虽具高危特征,但既定联合化疗、新型表面抗原靶向治疗和异基因HCT对多数患者有效,医学上适合的患者应接受这些治疗。
- 停用来那度胺后5例患者B-ALL或具B-ALL免疫表型的未成熟B细胞群消退,提示来那度胺可能在淋巴母细胞肿瘤发生后仍驱动白血病进展,作者认为单停用来那度胺可能为选定患者合适的一线干预。
- 监测早期B-ALL样增殖可能为停用来那度胺以预防进展提供机会。
研究设计与样本
- 双中心回顾性研究,纳入32例来那度胺维持治疗后发生的ALL病例(均为B系,31/32 BCR::ABL阴性)。
主要发现
- B-ALL诊断于首次暴露来那度胺后中位54个月(范围5-119),累积来那度胺暴露中位42个月(范围2-114)。
- 可评估病例中TP53突变9/19,低亚二倍体8/26。
- 尽管队列中位年龄65岁且具不良风险B-ALL特征,接受治疗患者CR或CRi率高(25/28)。
- 接受治疗患者中位无事件生存期35.4个月,接受异基因造血干细胞移植(HCT)者中位EFS未达到。
- 16例患者在HCT或延长维持治疗后仍存活且无B-ALL证据,5例停用来那度胺后B-ALL或具B-ALL免疫表型的未成熟B细胞群消退。
临床怎么用
- 作者建议,既定联合化疗方案、新型表面抗原靶向方法和异基因HCT对许多来那度胺相关B-ALL患者有效,应提供给医学上适合的患者。
- 作者认为,单停用来那度胺可能为选定患者合适的一线干预。
- 作者提出,监测早期B-ALL样增殖可能为停用来那度胺以预防进展提供机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide is an effective component of induction and maintenance therapy for multiple myeloma, though with a risk of secondary malignancies, including acute lymphoblastic leukemia (ALL). In contrast to therapy-related myeloid neoplasia, lenalidomide-associated lymphoblastic neoplasia remains poorly characterized. We conducted a dual institution retrospective study of 32 ALL cases that arose after lenalidomide maintenance (all B-lineage, 31/32 BCR::ABL-negative). B-cell ALL (B-ALL) was diagnosed at median 54 months (range, 5-119) after first exposure to lenalidomide and after median 42 months of cumulative lenalidomide exposure (range, 2-114). High incidence of TP53 mutations (9/19 evaluable cases) and low hypodiploidy (8/26 patients) were identified. Despite median age of 65 years and poor-risk B-ALL features observed in the cohort, rates of complete response (CR) or CR with incomplete hematologic recovery were high (25/28 patients receiving treatment). Median event-free survival was 35.4 months among treated patients (not reached among those undergoing allogeneic hematopoietic cell transplantation [HCT]). Sixteen patients remain alive without evidence of B-ALL after HCT or extended maintenance therapy. We also describe regression of B-ALL or immature B-cell populations with B-ALL immunophenotype after lenalidomide discontinuation in 5 patients, suggesting lenalidomide may drive leukemic progression even after initiation of lymphoblastic neoplasia and that lenalidomide withdrawal alone may be an appropriate first-line intervention in selected patients. Monitoring for early B-ALL-like proliferations may offer opportunities for lenalidomide withdrawal to prevent progression. Established combination chemotherapy regimens, newer surface antigen-targeted approaches, and allogeneic HCT are effective in many patients with lenalidomide-associated B-ALL and should be offered to medically fit patients.
引用
- Geyer MB, Shaffer BC, Bhatnagar B, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv. 2023. PMID: 36827680. doi:10.1182/bloodadvances.2022009212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。